Loading clinical trials...
Loading clinical trials...
The MIGHT Trial - An Exploratory Clinical Trial of Intravenous Immunoglobulin (IVIG) in Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Immune Mediated Necrotizing Myopathy (IMNM)
Conditions
Interventions
Intravenously administered pooled human immunoglobulin (IVIG)
Locations
5
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Johns Hopkins University
Baltimore, Maryland, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
University of Texas Health Science Center at Houston
Houston, Texas, United States
University of Washington
Seattle, Washington, United States
Start Date
October 27, 2025
Primary Completion Date
December 30, 2026
Completion Date
June 30, 2027
Last Updated
February 24, 2026
Lead Sponsor
University of Alabama at Birmingham
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions